TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 17680290

Group type: EXPERIMENTAL
Intervention: PUFA meal with high cholesterol (PUFA‐HC)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Dairy fat (DF) meal
Number of subjects: 16

Group type: COMPARATOR
Intervention: Type of meal (PUFA vs DF)
Number of subjects: 16
Study: 15522756

Group type: EXPERIMENTAL
Intervention: Topical application of 45S5 bioactive glass (10% solution), applied daily (2 x 1 h) during the preventive and therapeutic phase (21 days non-hygiene phase and 7 days therapeutic phase)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Topical application of 45S5 bioactive glass (10% solution)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (contralateral teeth without bioactive glass application)
Number of subjects: 0
Study: 12043769

Group type: EXPERIMENTAL
Intervention: Active ESWT (1500 pulses at 0.12 mJ/mm2)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 74
Study: 10438968

Group type: EXPERIMENTAL
Intervention: Mycobacterium bovis bacillus Calmette-Guérin (BCG) vaccination at birth
Number of subjects: 0

Group type: COMPARATOR
Intervention: Mycobacterium bovis bacillus Calmette-Guérin (BCG) vaccination later in life
Number of subjects: 0
Study: 7598277

Group type: EXPERIMENTAL
Intervention: Cisatracurium
Number of subjects: 58

Group type: COMPARATOR
Intervention: Vecuronium
Number of subjects: 58
Study: 2358274

Group type: EXPERIMENTAL
Intervention: Aulhorn flicker test
Number of subjects: 405

Group type: EXPERIMENTAL
Intervention: Visual evoked potentials (VEP)
Number of subjects: 405

Group type: EXPERIMENTAL
Intervention: Combination of Aulhorn flicker test and VEP
Number of subjects: 405
Study: 391257

Group type: EXPERIMENTAL
Intervention: Sodium valproate (1200 mg daily for 7 days)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control (no valproic acid)
Number of subjects: 8
Study: 31385203

Group type: EXPERIMENTAL
Intervention: Cognitive and physical training program
Number of subjects: 93

Group type: COMPARATOR
Intervention: Usual standard care
Number of subjects: 93
Study: 31060528

Group type: EXPERIMENTAL
Intervention: SWEL (Social Wellbeing and Engaged Living) intervention
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Befriending intervention
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Single Session Psycho-Education
Number of subjects: 0
Study: 28074355

Group type: EXPERIMENTAL
Intervention: Visual pedagogy intervention in dental check-ups and preventive practices
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (no visual pedagogy intervention)
Number of subjects: 40
Study: 25254902

Group type: EXPERIMENTAL
Intervention: 0.125% bupivacaine and fentanyl 2 μg/ml
Number of subjects: 310

Group type: COMPARATOR
Intervention: Fentanyl 10 μg/ml alone
Number of subjects: 310
Study: 23942329

Group type: COMPARATOR
Intervention: CHOP (n=48)
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: R-CHOP (n=45)
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: R-CHOP (BCL2 positive ABC subtypes)
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: R-CHOP (LMO2 positive ABC subtypes)
Number of subjects: 93
Study: 21270174

Group type: EXPERIMENTAL
Intervention: Insulin degludec (IDeg) A (600 μmol/L)
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: Insulin degludec (IDeg) B (900 μmol/L)
Number of subjects: 178

Group type: COMPARATOR
Intervention: Insulin glargine (IGlar)
Number of subjects: 178
Study: 18563061

Group type: EXPERIMENTAL
Intervention: Regular cigarette
Number of subjects: 62

Group type: COMPARATOR
Intervention: Denicotinized cigarette
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Total group
Number of subjects: 62
Study: 16925010

Group type: EXPERIMENTAL
Intervention: Chewing gum during lecture, lab, and studying
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Self-study CD
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard lecture + lab
Number of subjects: 0
Study: 14983962

Group type: EXPERIMENTAL
Intervention: Initial PSA < 4 ng/mL
Number of subjects: 21169

Group type: EXPERIMENTAL
Intervention: Initial PSA < 1 ng/mL, age < 55 years, first 18 months
Number of subjects: 21169

Group type: EXPERIMENTAL
Intervention: Initial PSA > 2.5 ng/mL, age < 55 years
Number of subjects: 21169

Group type: EXPERIMENTAL
Intervention: Interval between determinations > 42 months
Number of subjects: 21169

Group type: EXPERIMENTAL
Intervention: Interval between determinations 18-42 months
Number of subjects: 21169

Group type: EXPERIMENTAL
Intervention: Every additional year of age
Number of subjects: 21169

Group type: EXPERIMENTAL
Intervention: Every unit of basal PSA
Number of subjects: 21169
Study: 10929878

Group type: EXPERIMENTAL
Intervention: Gemifloxacin 320 mg p.o. 3 h after sucralfate (2 g)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Gemifloxacin 320 mg p.o. 3 h after ferrous sulphate (325 mg)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Gemifloxacin 320 mg p.o. 2 h before sucralfate
Number of subjects: 27

Group type: COMPARATOR
Intervention: Gemifloxacin 320 mg p.o. 2 h before ferrous sulphate
Number of subjects: 27
Study: 8957726

Group type: EXPERIMENTAL
Intervention: Cirrhotic patients
Number of subjects: 36

Group type: COMPARATOR
Intervention: Normal volunteers
Number of subjects: 36
Study: 1398631

Group type: EXPERIMENTAL
Intervention: Diagnostic formulas Ya and Yc
Number of subjects: 212
Study: 3927357

Group type: EXPERIMENTAL
Intervention: Nitrazepam 5 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Lormetazepam 1 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 30471452

Group type: EXPERIMENTAL
Intervention: Measuring units based on other body part
Number of subjects: 0

Group type: COMPARATOR
Intervention: Measuring units based on non-body object
Number of subjects: 0
Study: 30269898

Group type: COMPARATOR
Intervention: Control
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: 30 g of whey protein microgels (WPM30)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: 50 g of whey protein microgels (WPM50)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: 50 g micellar casein (MC50)
Number of subjects: 17
Study: 29029015

Group type: EXPERIMENTAL
Intervention: Tapentadol 100 mg
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Tapentadol 150 mg
Number of subjects: 15

Group type: COMPARATOR
Intervention: Oxycodone 20 mg
Number of subjects: 15
Study: 25449224

Group type: EXPERIMENTAL
Intervention: Occlusive wrap
Number of subjects: 801

Group type: COMPARATOR
Intervention: No wrap
Number of subjects: 801
Study: 23545347

Group type: EXPERIMENTAL
Intervention: Ulinastatin (20,000 units/kg)
Number of subjects: 36

Group type: COMPARATOR
Intervention: 0.9% saline (control)
Number of subjects: 36
Study: 21469532

Group type: EXPERIMENTAL
Intervention: Participants with BMI <35 and weight < 102 kg
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Participants with BMI >35 and weight >102 kg
Number of subjects: 51
Study: 19453581

Group type: EXPERIMENTAL
Intervention: Liberal group (allowed to eat and drink upon request)
Number of subjects: 147

Group type: COMPARATOR
Intervention: Fasting group (fasted for 6 hours)
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: Liberal group
Number of subjects: 147
Study: 16461133

Group type: EXPERIMENTAL
Intervention: 100,000 SQ-U
Number of subjects: 410

Group type: EXPERIMENTAL
Intervention: 10,000 SQ-U
Number of subjects: 410

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 410

Group type: EXPERIMENTAL
Intervention: Quality-of-life measures
Number of subjects: 410
Study: 15265255

Group type: EXPERIMENTAL
Intervention: ABC/COM (abacavir 300 mg + lamivudine 150 mg/zidovudine 300 mg combination tablet)
Number of subjects: 342

Group type: COMPARATOR
Intervention: IDV/COM (indinavir 800 mg + lamivudine 150 mg/zidovudine 300 mg combination tablet)
Number of subjects: 342
Study: 11975764

Group type: EXPERIMENTAL
Intervention: Pravastatin 40 mg daily at bedtime
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Simvastatin 80 mg each evening
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Lovastatin
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Fluvastatin
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Atorvastatin
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Pravastatin
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Simvastatin
Number of subjects: 21
Study: 9043473

Group type: EXPERIMENTAL
Intervention: Dietary advice and protein‐rich supplements for 4 months
Number of subjects: 53

Group type: COMPARATOR
Intervention: Standard management
Number of subjects: 53
Study: 7938088

Group type: EXPERIMENTAL
Intervention: Potassium depletion treatment (KD1, KD2, KD3)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Potassium depletion treatment (KD2, KD3)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Potassium depletion treatment (KD3)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Normokalemic controls (N)
Number of subjects: 20
Study: 2965159

Group type: EXPERIMENTAL
Intervention: 28-amino acid human atrial natriuretic peptide (hANP-(99-126))
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: 26-amino acid human atrial natriuretic peptide (ANP-(101-126))
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 31679408

Group type: EXPERIMENTAL
Intervention: N-acetyl cysteine (NAC) 200 mg dissolved in water
Number of subjects: 58

Group type: COMPARATOR
Intervention: 0.12% chlorhexidine digluconate (CHX) mouthwash
Number of subjects: 58
Study: 29273262

Group type: EXPERIMENTAL
Intervention: Continuous hyperfractionated accelerated radiotherapy weekend-less (CHARTWEL)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Conventional fractionated radiotherapy (CF)
Number of subjects: 160
Study: 26868074

Group type: EXPERIMENTAL
Intervention: Fetal Pillow
Number of subjects: 240

Group type: COMPARATOR
Intervention: Control (without Fetal Pillow)
Number of subjects: 240
Study: 24232638

Group type: EXPERIMENTAL
Intervention: Multidisciplinary intervention program
Number of subjects: 75

Group type: COMPARATOR
Intervention: Usual-care program
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Both groups combined
Number of subjects: 75
Study: 23281842

Group type: EXPERIMENTAL
Intervention: ergocalciferol, 50.000 IU/week for 6 weeks
Number of subjects: 43

Group type: COMPARATOR
Intervention: Control group (no ergocalciferol treatment)
Number of subjects: 43
Study: 20173087

Group type: EXPERIMENTAL
Intervention: Cisplatinum during HIPEC
Number of subjects: 40
Study: 19892915

Group type: EXPERIMENTAL
Intervention: Glutaraldehyde-induced cross-linking
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Grape seed extract-induced cross-linking
Number of subjects: 0
Study: 16982281

Group type: EXPERIMENTAL
Intervention: 15% citric acid plus 2.5% NaOCl
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: 15% EDTA plus 2.5% NaOCl
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: 5% orthophosphoric acid plus 2.5% NaOCl
Number of subjects: 80

Group type: COMPARATOR
Intervention: 2.5% NaOCl
Number of subjects: 80
Study: 15765034

Group type: EXPERIMENTAL
Intervention: Immediate ambulation with compression stockings
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Immediate ambulation with Unna boot bandages
Number of subjects: 53

Group type: COMPARATOR
Intervention: Bed rest with no compression
Number of subjects: 53
Study: 11195984

Group type: EXPERIMENTAL
Intervention: Induction of a threatening interpretation of ambiguous information
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Induction of a benign interpretation of ambiguous information
Number of subjects: 0

Group type: COMPARATOR
Intervention: Baseline condition
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Active processing of personally relevant meanings
Number of subjects: 0
Study: 9285181

Group type: EXPERIMENTAL
Intervention: Trandolapril
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Trandolapril (ID genotype)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo (ID genotype)
Number of subjects: 56
Study: 8301065

Group type: EXPERIMENTAL
Intervention: Sclerotherapy plus propranolol
Number of subjects: 85

Group type: COMPARATOR
Intervention: Sclerotherapy alone
Number of subjects: 85
Study: 3579659

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Amitriptyline
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Propranolol vs Amitriptyline
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Propranolol and Amitriptyline
Number of subjects: 30
Study: 31311427

Group type: EXPERIMENTAL
Intervention: Switch condition (change between fore- and rear-foot strike pattern every 30 s during downhill sections)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control condition (without change in foot strike pattern)
Number of subjects: 14
Study: 28849682

Group type: EXPERIMENTAL
Intervention: Vitamin D3 supplementation (100,000 IU monthly)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65
Study: 26335670

Group type: EXPERIMENTAL
Intervention: Guardians
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: Patients
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: Patients and Guardians
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: Older patient age (>12 years), guardian with a college degree, obtaining consent by the attending surgeon, separate preoperative visit, use of visual aids, participation in a peer-support group
Number of subjects: 176
Study: 26310180

Group type: EXPERIMENTAL
Intervention: Polyamide monofilaments (bending force: 0.2, 69 and 2569mN) and a 'weighted-pin' stimulator (512mN)
Number of subjects: 23
Study: 23003342

Group type: EXPERIMENTAL
Intervention: Azithromycin smart gel system (formulated with Pluronic® F‐127 and Hydroxy Ethyl Cellulose)
Number of subjects: 0
Study: 15931642

Group type: EXPERIMENTAL
Intervention: Acetate-free biofiltration (AFB) with polyacrilonitrile filters for 4 hr thrice-weekly
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Acetate-free biofiltration (AFB)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control group (24 healthy volunteers, 12 females, 12 males, mean age 55 +/- 9 yrs)
Number of subjects: 48
Study: 14695360

Group type: EXPERIMENTAL
Intervention: Nutrition group
Number of subjects: 213

Group type: EXPERIMENTAL
Intervention: Physical activity group
Number of subjects: 213

Group type: EXPERIMENTAL
Intervention: Combined nutrition and physical activity group
Number of subjects: 213

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 213
Study: 10215729

Group type: EXPERIMENTAL
Intervention: Ranitidine 75 mg
Number of subjects: 1489

Group type: EXPERIMENTAL
Intervention: Ranitidine 25 mg
Number of subjects: 1489

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1489
Study: 8829785

Group type: EXPERIMENTAL
Intervention: Teams of case managers plus peer specialists
Number of subjects: 104

Group type: COMPARATOR
Intervention: Teams of case managers plus nonconsumer assistants
Number of subjects: 104

Group type: COMPARATOR
Intervention: Case managers only
Number of subjects: 104
Study: 2157554

Group type: COMPARATOR
Intervention: CDDP (120 mg/m2 x 3 weeks)
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: CDDP (120 mg/m2) and VP‐16 (100 mg/m2 given i.v. on days 1‐3, repeated every 3 weeks)
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: CDDP (120 mg/m2), VP‐16 (100 mg/m2 on days 1‐3), and mitomycin C (10 mg/m2 on days 1, 21, and 42, then every 6 weeks, for a maximal dose of 100 mg)
Number of subjects: 156

Group type: COMPARATOR
Intervention: CDDP alone
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Combination chemotherapy (CDDP/VP‐16)
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Mitomycin C addition
Number of subjects: 156
Study: 374164

Group type: EXPERIMENTAL
Intervention: Phyllocontin Continus tablets
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 29565189

Group type: EXPERIMENTAL
Intervention: INDICORE intervention (multi-faceted training on diagnostics for PCPs, supported by patient education material and a referral process tool)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Generic communication training for all clusters (control group)
Number of subjects: 0
Study: 27402283

Group type: EXPERIMENTAL
Intervention: Ice application with scheduled over-the-counter analgesics (n=36)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Scheduled over-the-counter analgesics alone (n=32)
Number of subjects: 68
Study: 26311629

Group type: EXPERIMENTAL
Intervention: Femtosecond laser-assisted cataract surgery (FLACS)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Conventional cataract surgery
Number of subjects: 54
Study: 24399584

Group type: EXPERIMENTAL
Intervention: Patients with anterior MI
Number of subjects: 24
Study: 20802298

Group type: EXPERIMENTAL
Intervention: LPV/r monotherapy
Number of subjects: 60

Group type: COMPARATOR
Intervention: Continued treatment
Number of subjects: 60
Study: 17651830

Group type: EXPERIMENTAL
Intervention: Hydration with 0.45% sodium chloride and acetylcysteine (1200 mg orally, twice loading dose at 12 hours before and immediately after procedure) in patients with elevated baseline creatinine.
Number of subjects: 936

Group type: COMPARATOR
Intervention: Hydration with 0.45% sodium chloride alone in patients with normal renal function.
Number of subjects: 936

Group type: EXPERIMENTAL
Intervention: Patients with CIN in the abnormal group.
Number of subjects: 936

Group type: EXPERIMENTAL
Intervention: Patients with elevated baseline creatinine levels.
Number of subjects: 936
Study: 15774607

Group type: EXPERIMENTAL
Intervention: Presence of a physician in prehospital setting
Number of subjects: 1639

Group type: EXPERIMENTAL
Intervention: Prehospital fibrinolysis
Number of subjects: 1639

Group type: EXPERIMENTAL
Intervention: Country of enrollment
Number of subjects: 1639
Study: 12460293

Group type: EXPERIMENTAL
Intervention: Novel lidocaine/tetracaine‐based cream peel (S‐Caine)
Number of subjects: 20

Group type: COMPARATOR
Intervention: EMLA cream with occlusion for 30 minutes
Number of subjects: 20
Study: 10337544

Group type: EXPERIMENTAL
Intervention: M-mode Doppler tissue imaging
Number of subjects: 64

Group type: COMPARATOR
Intervention: Control group (11 matched healthy volunteers)
Number of subjects: 64
Study: 8748192

Group type: EXPERIMENTAL
Intervention: Triple-hormone infusion (epinephrine, glucagon, hydrocortisone)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Saline infusion (control)
Number of subjects: 0
Study: 1823392

Group type: EXPERIMENTAL
Intervention: Intravenous magnesium for 2 days followed by oral magnesium (n = 12)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo (n = 13)
Number of subjects: 25
Study: 7282519

Group type: EXPERIMENTAL
Intervention: Furosemide (FUR) added to propranolol
Number of subjects: 40

Group type: COMPARATOR
Intervention: Hydrochlorothiazide (HCT) added to propranolol
Number of subjects: 40
Study: 31796515

Group type: EXPERIMENTAL
Intervention: NanoCind® signature
Number of subjects: 60
Study: 27976374

Group type: EXPERIMENTAL
Intervention: Cognitive Therapy for PTSD (CT-PTSD)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Waiting List (WL)
Number of subjects: 29
Study: 26098004

Group type: EXPERIMENTAL
Intervention: Home treatment (early discharge followed by home treatment in combination with inpatient treatment)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Regular length inpatient treatment (control group)
Number of subjects: 92
Study: 23535987

Group type: COMPARATOR
Intervention: Visit-to-visit variability metrics (s.d., SDIM, CV, SV, ARV, range, maximum, peak size, trough size)
Number of subjects: 288
Study: 21317771

Group type: EXPERIMENTAL
Intervention: Acupuncture treatment
Number of subjects: 9990

Group type: COMPARATOR
Intervention: Routine care (Control)
Number of subjects: 9990
Study: 21650071

Group type: EXPERIMENTAL
Intervention: Bedside inoculation of culture media with CSF
Number of subjects: 220

Group type: COMPARATOR
Intervention: Laboratory inoculation of culture media with CSF
Number of subjects: 220
Study: 16981176

Group type: EXPERIMENTAL
Intervention: Adjustment for measurement error using regression calibration
Number of subjects: 0
Study: 15034156

Group type: EXPERIMENTAL
Intervention: Enoxaparin
Number of subjects: 20

Group type: COMPARATOR
Intervention: Unfractionated Heparin (UFH)
Number of subjects: 20
Study: 11605928

Group type: EXPERIMENTAL
Intervention: Synchronized intermittent mandatory ventilation (SIMV) at 0 breaths/min
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Synchronized intermittent mandatory ventilation (SIMV) at 5 breaths/min
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Synchronized intermittent mandatory ventilation (SIMV) at 10 breaths/min
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Synchronized intermittent mandatory ventilation (SIMV) at 15 breaths/min
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Synchronized intermittent mandatory ventilation (SIMV) at 20 breaths/min
Number of subjects: 11
Study: 9682686

Group type: EXPERIMENTAL
Intervention: HMO members in the intervention group
Number of subjects: 2316

Group type: EXPERIMENTAL
Intervention: Non-HMO patients in the intervention group
Number of subjects: 2316
Study: 8202788

Group type: EXPERIMENTAL
Intervention: Aerobic exercise program (12-week duration)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Untrained control subjects (no aerobic exercise)
Number of subjects: 37
Study: 2532458

Group type: EXPERIMENTAL
Intervention: Cilazapril 1 mg once daily for 4 weeks, then increased to 2.5 mg once daily for 4 weeks, and further increased to 5 mg if necessary
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Cilazapril
Number of subjects: 83
Study: 1055560

Group type: EXPERIMENTAL
Intervention: DMSO spray (2 ml applied in the posterior pharynx and tonsil region, 1 to 4 applications)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: DMSO spray
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (similar treatment without DMSO spray)
Number of subjects: 60
Study: 29867044

Group type: EXPERIMENTAL
Intervention: Web-based educational intervention using a specially designed internet platform and educational materials prepared by a physician specialized in clinical oncology.
Number of subjects: 463

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned).
Number of subjects: 463
Study: 29798102

Group type: EXPERIMENTAL
Intervention: Chitosan nerve conduit with PRP (Group A)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Chitosan nerve conduit with saline (Group B)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Silicone tube with saline (Group C)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Silicone tube with PRP (Group D)
Number of subjects: 40